CNST News and Press, Constellation Pharmaceuticals Inc. From 02/24/21

Constellation Pharmaceuticals, Inc. (CNST) Q4 2020 Earnings Conference Call February 24, 2021 08:00 AM ET Company Participants Kia Khaleghpour - Vice President, Investor Relations & Communications Jigar Raythatha - President & Chief Executive Officer Brendan Delaney - Chief Commercial...

Gainers: Sypris Solutions (SYPR) +83%.9F (JFU) +39%.Owens & Minor (OMI) +38%.Sunworks (SUNW) +34%.R. R. Donnelley & Sons (RRD) +30%.Fisker (FSR) +28%.PubMatic (PUBM) +27%.dMY Technology (DMYI) +26%.Timber Pharmaceuticals (TMBR) +25%.Cancer Genetics (CGIX) +25%.Losers: C...

The following slide deck was published by Constellation Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Constellation Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation

Gainers: Sunesis Pharmaceuticals (SNSS) +38%, Owens & Minor (OMI) +32%, Salarius Pharmaceuticals (SLRX) +20%, Poseida Therapeutics (PSTX) +20%, PRA Health Sciences (PRAH) +19%.Losers: Rafael (RFL) -12%, Constellation Pharmaceuticals (CNST)...

Constellation Pharmaceuticals (CNST): Q4 GAAP EPS of -$0.79 misses by $0.04.Cash, cash equivalents, and marketable securities as of December 31, 2020, were $421.4 million. Press Release For further details see: Constellation Pharmaceuticals EPS misses by $0.04

CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its fourth-quarter 2020 financial results and provided...

CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate i...

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on February 24, 2021, to discuss...

CNST's CPI-0610 has excellent Phase 2 data in MF. Its SVR35 and TSS50 data compares favourably with other drugs in development and with Jakafi. Current low prices make it a speculative bet. For further details see: Constellation Pharma: CPI-0610 Is Well-Differentiated In...

Constellation Pharmaceuticals ([[CNST]] +5.4%) appoints Brendan Delaney to the newly created position of Chief Commercial Officer, effective January 11, 2021. In this role, Mr. Delaney will be responsible for building and leading the company’s commercial organizatio...